Legislation & Regulation

Press Release: The Academy of Managed Care Pharmacy (AMCP) commends the U.S. Food and Drug Administration (FDA) for issuing final guidance that clarifies how manufacturers can communicate truthful and non-misleading information with payers across a product’s lifecycle.

AMCP letter to Chairman Grassley and Ranking Member Feinstein of the Senate Judiciary Committee

AMCP webinar that detailed the Trump Administration’s American Patients First proposal for addressing the rising cost of pharmaceuticals.

Press Release: AMCP CEO Susan A. Cantrell, RPh, CAE, Responds to President Trump’s Speech on Lowering Drug Costs

AMCP comments on the Letter for the Record to House Energy and Commerce Committee in Support of Opioid Legislation - H.R. 3528, H.R. 4275 and H.R. 4841.

On April 2, 2018 CMS released the Final CY 2019 Call Letter for Medicare Advantage (MA) and Medicare Part D Plans. There were no substantial changes to the proposals included in the Draft Call Letter, which were finalized generally as proposed. The agency did update the Standard Benefit Parameters to reflect the changes to the coverage gap that were included in the Bipartisan Budget Act of 2018.

AMCP CEO Blog: One of AMCP’s key strategic pillars is to advocate for legislation that will help advance the profession of managed care pharmacy. This function is on full display this week during our Annual Legislative Days event.

On March 5, 2018, AMCP provided comments in response to the Advance Summary of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter. AMCP comments focus on the sections of the notice related to CMS's proposal on several new strategies for identifying potential opioid abuse.